134.74 -0.20 (-0.15%)
Pre-Market: 7:28AM EST
|Bid||134.57 x 1000|
|Ask||134.93 x 2200|
|Day's Range||130.78 - 134.97|
|52 Week Range||121.00 - 148.99|
|Beta (3Y Monthly)||0.70|
|PE Ratio (TTM)||25.74|
|Earnings Date||Jan 21, 2020|
|Forward Dividend & Yield||3.80 (2.90%)|
|1y Target Est||150.24|
A look at how portfolio assets can be periodically rebalanced (from better-performing asset classes to underperformers, for example) and occasionally sold to supplement income for retirees.
Immunology drug scheduled to supplant the widely used heart medication Lipitor, tallying cumulative sales of $240 billion Continue reading...
We believe one of the best tools for ordinary investors who are on the hunt for new ideas is 13F filings. Once every quarter hedge funds with at least $100 million in total positions in publicly traded US stocks/options are required to open the kimono and disclose the number of shares and the total value of […]
An Oklahoma judge on Friday said Johnson & Johnson must pay that state $465 million for fueling the opioid epidemic through the deceptive marketing of painkillers, down from his original award of $572 million. The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma, came in the first case to go to trial out of 2,700 nationally by states, counties and cities seeking to hold drug companies responsible for the deadly epidemic. Balkman reduced the amount he had awarded in August by $107 million after agreeing with New Brunswick, New Jersey-based J&J that he had made a math error.
The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma, came in the first case to go to trial out of 2,700 nationally by states, counties and cities seeking to hold drug companies responsible for the deadly epidemic. Balkman reduced the amount he had awarded in August by $107 million after agreeing with New Brunswick, New Jersey-based J&J that he had made a math error. A spokesman for Oklahoma Attorney General Mike Hunter said that office is reviewing the decision and will formally respond within the next few days.
Startup accelerator Founders Factory is launching in New York. This marks the organization's fourth location overall, but its first effort at expansion in the U.S. The move was made possible thanks to Johnson & Johnson (NYSE: JNJ), which came on as an anchor investor. The other Founders Factory locations are in London, Johannesburg and Paris.
Serial dividend raisers, such as the Dividend Aristocrats, are beloved by income hunters. Remember: A steady payout is only half of the formula for successful income investing. The big returns come over time, from regular dividend increases, which lift the yield an investor receives on his or her original cost basis.But while these dividend-hiking stalwarts usually aren't known for their hot growth prospects, a few are indeed poised to outperform in 2020.To find price upside among dependable dividend stocks, we started with the Dividend Aristocrats. For the uninitiated, the Aristocrats are an index of 57 S&P; 500 companies currently that have raised their payouts annually for at least 25 years.Next, we calculated the implied upside for all 57 Aristocrats based on analysts' average price targets. A price target is the level at which analysts forecast a stock will trade at some point in the future, typically 12 months out.After running the numbers, we were left with 10 Dividend Aristocrats that offered projected upside of at least 10% in the year ahead. Add in the contributions from their dividends, and these primarily defensive stocks may deliver significant offense in 2020. SEE ALSO: 14 High-Yield Dividend Stocks to Buy for the 4% Rule
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Health authorities in eastern Congo have introduced a new Ebola vaccine produced by Johnson & Johnson, aid group MSF said on Thursday, to help combat the world's second-worst outbreak of the virus on record. New tools including vaccines have helped contain the outbreak, second only to the 2013-16 West African outbreak that killed more than 11,300, despite public mistrust and conflict affecting the response in parts of the region. The new vaccine, which has passed clinical trials but has never been tested in a real-world setting, will be administered to 50,000 people in Goma, a city of two million on the Rwandan border, Médecins Sans Frontières (MSF) said in a statement.
TORONTO/MONTREAL, Nov 13 (Reuters) - Johnson & Johnson's Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec's public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows. The plan's administrator stopped covering Remicade, J&J unit Janssen's version of the drug infliximab, for some new patients in February 2017, in favor of cheap near-copies called biosimilars, mainly Pfizer Inc's version of infliximab, called Inflectra. In January, a Quebec court ordered it to resume coverage.
On Oct. 15, Johnson & Johnson (NYSE:JNJ), the healthcare giant, reported Q3 earnings and revenue that beat analysts' average expectations. Yet, over the past 12 months, JNJ stock is down about 9%.Source: Alexander Tolstykh / Shutterstock.com Now many investors are wondering whether the company may end the year on a high note. In the next few weeks, I expect Johnson & Johnson shares to trade mostly between a range of $125 and $135. Long-term investors may view any upcoming weakness in the JNJ stock price as an opportunity to buy the shares. Analyzing JNJ's Recent EarningsWith a market cap of $347 billion, Johnson & Johnson, the healthcare giant, is currently number 37 on the Fortune 500 list. JNJ 's third-quarter revenue rose 1.9% year-over-year to $20.7 billion. Its earnings per share, excluding certain items, came in at $2.12, versus analysts' average estimate of $2.01.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Tech Stocks to Buy for the Rest of 2019 The company has a broad-based business model with a global reach. It operates in three segments that provide it with diversified sources of revenue, earnings and cash flow: * Pharmaceutical, which contributes more than 50% of JNJ's pretax profits * Consumer * Medical DevicesJNJ's pharmaceutical division markets treatments for immunology, cardiovascular and metabolic diseases, pulmonary hypertension, infectious diseases and cancer.Several of its well-known consumer brands include Aveeno, Band-Aid, Johnson's Baby, Listerine, Neutrogena, Rogaine, Tylenol and Zyrtec.Finally,its medical devices business develops and markets products and solutions for surgery, orthopedics, and vision.Although about 60% of Johnson &Johnson's revenue is U.S.-based, its overseas operations in general and its emerging market businesses in particular are proving to be important growth catalysts for JNJ. The Legal Woes of Johnson & JohnsonPharmaceutical industry firms often face legal challenges. At present, Johnson & Johnson is facing literally thousands of lawsuits.For example, in the summer, the Federal Trade Commission issued civil subpoenas to the company in an effort to determine whether JNJ had violated antitrust laws with Remicade, its rheumatoid arthritis drug.In August, Johnson and Johnson made the news when an Oklahoma judge found it guilty of helping to fuel the state's opioid crisis by aggressively marketing painkillers. JNJ is also facing various lawsuits regarding its talc-based baby powder.Recent research by Theresa Gabaldon of George Washington University Law School discusses in detail the "ballooning of pharmaceutical advertising with correlative increases in the prescriptions written for various mental and other ailments" within the industry.Professor Gabaldon further states that "Purdue Pharma led off in the 1990s by heavily advertising OxyContin as non-addictive--a claim that clearly was untrue." AbbVie (NYSE:ABBV), Johnson & Johnson, and Pfizer (NYSE:PFE) "also conducted aggressive advertising campaigns for their proprietary opioids. These campaigns, which were directed at physicians, resulted in $11 billion from opioid sales alone in 2010."In the long-run, lawsuits and fines do not necessarily dent the fundamental metrics of pharma companies much. However, in the short-term, investors understandably get spooked by the uncertainty created by lawsuits. Other Long-Term Factors to ConsiderOne of the challenges faced by JNJ and other drug companies is falling sales as the patents of blockbuster drugs expire, enabling much cheaper, competing generic drugs to be sold.Therefore, the pressure to innovate and diversify is part of the reality of managing a global pharma leader like Johnson & Johnson. And in JNJ's case, diversification has been the company's competitive advantage. As one segment faces headwinds, the others usually help propel the company forward.The forward price-earnings ratio of JNJ stock stands at 14.5 and is lower than many of its peers. Many investors would cbe comfortable paying more than that for a strong business like Johnson & Johnson.Meanwhile, Johnson & Johnson stock also has a dividend yield of 2.9%. The conglomerate has raised its dividend each year for over half a century. And dividends tend to create a "price floor" for coveted stocks such as JNJ. What Technical Charts IndicateNo investor has a crystal ball that can predict the markets' next move. However, analyzing the recent price action of JNJ stock may give us an indication of what to expect in the weeks ahead.In 2019 JNJ stock has fallen 1.6%. Its 52-week range has been $121.00 (Dec. 24, 2018) - $148.99 (Dec. 4, 2018).JNJ's short-term charts are painting a mixed picture and suggest that JNJ stock is likely to trade within a range. While long-term investors would like to see JNJ stock stay over $135, short-term traders are likely to keep the shares between $125 and $135.I do not expect Johnson & Johnson stock to reach any new highs until we have more clarity on the full ramification of several of its legal challenges.In recent weeks, the stock has found support around the $125 level. Therefore, I'd consider buying the shares if they fall toward or even below first $125 and then $120. The Bottom Line on JNJ StockThe company's diversification enables JNJ stock to withstand economic cycles more effectively. No matter what the economy does, consumers will buy the products of many of its strong brands, and Johnson & Johnson will likely have industry-leading market share in many areas.I remain bullish on the long-term outlook of Johnson and Johnson stock. However, in the short-term, JNJ might exhibit weakness.Therefore, investors may consider staying on the sidelines on JNJ if they do not currently have a position in the shares.Alternatively, investors who already own the shares may consider hedging their positions. As for hedging strategies, covered calls with a Jan. 17 expiry could be appropriate.Finally, any short-term decline in these shares may create better entry points for long-term investors who do not yet own JNJ stock.As of this writing, Tezcan Gecgil hold PFE covered calls (Nov. 15 expiry). More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks to Buy for the Rest of 2019 * 7 Biotech Stocks to Buy With Plenty of Power in the Pipeline * 5 Stocks to Buy That Are Set for Monster Growth in 2020 The post Should Investors Add Johnson & Johnson Stock to Their Shopping Lists? appeared first on InvestorPlace.
ABT stock is one of the biggest diversified medical stocks behind Johnson & Johnson and Roche. As it aims for clearance of its Freestyle Libre 2, is it time to buy Abbott stock?
New York's insurance regulator has formally notified a group of opioid manufacturers and distributors that it will launch a civil enforcement action against them for contributing towards a rise in health insurance premiums in the state, said two sources familiar with the matter. The New York State Department of Financial Services (NYDFS) has sent letters to around 23 opioid manufacturers and distributors, notifying them that the regulator would begin the process to hold a hearing on the issue in an administrative proceeding, the sources said.
Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.
TORONTO/MONTREAL, Nov 13 (Reuters) - Johnson & Johnson's Remicade, a blockbuster drug that treats autoimmune disorders, has steadily lost market share among patients enrolled in the Canadian province of Quebec's public drug program, even after a court ruling reinstated full coverage in January, a Reuters analysis of government data shows. The plan's administrator stopped covering Remicade, J&J unit Janssen's version of the drug infliximab, for some new patients in February 2017, in favor of cheap near-copies called biosimilars, mainly Pfizer Inc's version of infliximab, called Inflectra.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Jabil Inc. New York, November 12, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Jabil Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
AbbVie (ABBV) submits a regulatory application with the FDA seeking label expansion of Imbruvica as a first-line treatment for chronic lymphocytic leukemia in combination with Roche's Rituxan.
Arrowhead Pharmaceuticals and Johnson & Johnson said Friday they eradicated nearly all traces of hepatitis B virus in a study — sending Arrowhead careening toward another record high.
Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.